サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：うっ血性心不全治療薬の世界市場レポート：産業分析、規模、シェア、成長、動向、予測（2023年～2030年）
市場調査レポート
商品コード
1377872

うっ血性心不全治療薬の世界市場レポート：産業分析、規模、シェア、成長、動向、予測（2023年～2030年）

Global Congestive Heart Failure Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日
ページ情報
英文 143 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.05円
うっ血性心不全治療薬の世界市場レポート：産業分析、規模、シェア、成長、動向、予測（2023年～2030年）
出版日: 2023年09月01日
発行: Value Market Research
ページ情報: 英文 143 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

うっ血性心不全治療薬の世界需要は、2023年～2030年の調査期間中にCAGR16.23%で成長し、2022年の72億9,000万米ドルから2030年までに242億8,000万米ドルの市場規模に達すると推定されます。

うっ血性心不全（CHF）治療薬は、心不全治療薬または心臓治療薬としても知られ、うっ血性心不全の管理および治療に使用される薬剤クラスです。うっ血性心不全は、冠動脈疾患、高血圧症、心臓弁障害、心筋症など、さまざまな根本的原因によって生じる可能性があります。

市場力学：

加齢や生活習慣に関連することが多い心不全の発生率の増加が、うっ血性心不全治療薬の需要を牽引しています。世界人口の高齢化に伴い、心不全のリスクが高い高齢者人口が増加していることも、この需要にさらに拍車をかけています。新薬や併用療法の開発など、薬物療法の進歩が心不全の管理を強化しています。医療従事者や患者の意識の高まりと規制当局の支援が、CHF治療薬の採用を促進しています。植え込み型心臓デバイスや遠隔医療などの技術の進歩は、薬物療法を補完し、患者のケアを向上させます。個別化医療は、薬物療法を個人のプロファイルに合わせて調整し、治療成果を最適化します。研究、臨床試験、共同研究は、患者の転帰とQOLの改善に焦点を当て、CHF治療薬開発の技術革新を推進し続けています。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールはうっ血性心不全治療薬の世界市場における各セグメントを包括的に評価することもできます。うっ血性心不全治療薬産業の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析：

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおけるうっ血性心不全治療薬市場の現在および将来の需要を強調する地域展望をカバーしています。さらに、本レポートは、すべての主要地域における個々の用途セグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 うっ血性心不全治療薬 - 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 うっ血性心不全治療薬の世界市場分析：薬剤クラス別

  • 概要：薬剤クラス別
  • 実績データと予測データ
  • 分析：薬剤クラス別
  • ACE阻害薬
  • アンジオテンシン2受容体遮断薬
  • β遮断薬
  • 利尿薬
  • アルドステロン拮抗薬
  • 強心薬
  • その他

第6章 うっ血性心不全治療薬の世界市場分析：流通チャネル別

  • 概要：流通チャネル別
  • 実績データと予測データ
  • 分析：流通チャネル別
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 うっ血性心不全治療薬の世界市場分析：地域別

  • 地域別の展望
  • イントロダクション
  • 北米の売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域の売上分析
    • 概要、実績と予測
    • アジア太平洋地域：セグメント別
    • アジア太平洋地域：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカの売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第8章 うっ血性心不全治療薬企業の競合情勢

  • うっ血性心不全治療薬の市場競争
  • 提携/協力/合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第9章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Bayer AG
  • Novartis AG
  • Merck & Co. Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Eli Lilly and Company
  • Novo Nordisk A/S.
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Drug Class (USD MN)
  • ACE Inhibitors Market Sales by Geography (USD MN)
  • Angiotensin 2 Receptor Blockers Market Sales by Geography (USD MN)
  • Beta Blockers Market Sales by Geography (USD MN)
  • Diuretics Market Sales by Geography (USD MN)
  • Aldosterone Antagonists Market Sales by Geography (USD MN)
  • Inotropes Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Congestive Heart Failure Drugs Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Congestive Heart Failure Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global Congestive Heart Failure Drugs Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Drug Class
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Drug Class (USD MN)
  • ACE Inhibitors Market Sales by Geography (USD MN)
  • Angiotensin 2 Receptor Blockers Market Sales by Geography (USD MN)
  • Beta Blockers Market Sales by Geography (USD MN)
  • Diuretics Market Sales by Geography (USD MN)
  • Aldosterone Antagonists Market Sales by Geography (USD MN)
  • Inotropes Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112112245

The global demand for Congestive Heart Failure Drugs Market is presumed to reach the market size of nearly USD 24.28 BN by 2030 from USD 7.29 BN in 2022 with a CAGR of 16.23% under the study period 2023 - 2030.

Congestive Heart Failure (CHF) drugs, also known as heart failure medications or cardiac medications, are a class of pharmaceuticals used to manage and treat congestive heart failure-a chronic medical condition in which the heart stops pumping blood effectively to meet the body's needs. It can result from various underlying causes, such as coronary artery disease, hypertension, heart valve disorders, or cardiomyopathy.

MARKET DYNAMICS:

The increasing incidence of heart failure, often associated with aging and lifestyle factors, is driving the demand for congestive heart failure medications. As the global population ages, a larger demographic of elderly individuals at higher risk of heart failure further contributes to this demand. Advancements in drug therapies, including the development of new medications and combination therapies, are enhancing the management of heart failure. Increased awareness among healthcare providers and patients, along with regulatory support, fosters the adoption of CHF drugs. Technological advancements, such as implantable cardiac devices and telemedicine, complement drug therapies and improve patient care. Personalized medicine tailors drug regimens to individual profiles, optimizing treatment outcomes. Research, clinical trials, and collaborations continue to drive innovation in CHF drug development, focusing on improving patient outcomes and quality of life.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of congestive heart failure drugs. The growth and trends of congestive heart failure drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the congestive heart failure drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • ACE Inhibitors
  • Angiotensin 2 Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Aldosterone Antagonists
  • Inotropes
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Congestive Heart Failure Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Congestive Heart Failure Drugs market include Bayer AG, Novartis AG, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim International GmbH, Pfizer, Inc., Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Novo Nordisk A/S. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . CONGESTIVE HEART FAILURE DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Distribution Channel
    • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET ANALYSIS BY DRUG CLASS

  • 5.1 Overview by Drug Class
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Drug Class
  • 5.4 ACE Inhibitors Historic and Forecast Sales by Regions
  • 5.5 Angiotensin 2 Receptor Blockers Historic and Forecast Sales by Regions
  • 5.6 Beta Blockers Historic and Forecast Sales by Regions
  • 5.7 Diuretics Historic and Forecast Sales by Regions
  • 5.8 Aldosterone Antagonists Historic and Forecast Sales by Regions
  • 5.9 Inotropes Historic and Forecast Sales by Regions
  • 5.10. Others Historic and Forecast Sales by Regions

6 . GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 6.1 Overview by Distribution Channel
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Distribution Channel
  • 6.4 Hospital Pharmacies Historic and Forecast Sales by Regions
  • 6.5 Retail Pharmacies Historic and Forecast Sales by Regions
  • 6.6 Online Pharmacies Historic and Forecast Sales by Regions

7 . GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 7.3.2. North America By Segment Sales Analysis
    • 7.3.3. North America By Country Sales Analysis
    • 7.3.4. United State Sales Analysis
    • 7.3.5. Canada Sales Analysis
    • 7.3.6. Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 7.4.2. Europe by Segment Sales Analysis
    • 7.4.3. Europe by Country Sales Analysis
    • 7.4.4. United Kingdom Sales Analysis
    • 7.4.5. France Sales Analysis
    • 7.4.6. Germany Sales Analysis
    • 7.4.7. Italy Sales Analysis
    • 7.4.8. Russia Sales Analysis
    • 7.4.9. Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 7.5.2. Asia Pacific by Segment Sales Analysis
    • 7.5.3. Asia Pacific by Country Sales Analysis
    • 7.5.4. China Sales Analysis
    • 7.5.5. India Sales Analysis
    • 7.5.6. Japan Sales Analysis
    • 7.5.7. South Korea Sales Analysis
    • 7.5.8. Australia Sales Analysis
    • 7.5.9. South East Asia Sales Analysis
    • 7.5.10. Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 7.6.2. Latin America by Segment Sales Analysis
    • 7.6.3. Latin America by Country Sales Analysis
    • 7.6.4. Brazil Sales Analysis
    • 7.6.5. Argentina Sales Analysis
    • 7.6.6. Peru Sales Analysis
    • 7.6.7. Chile Sales Analysis
    • 7.6.8. Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 7.7.2. Middle East & Africa by Segment Sales Analysis
    • 7.7.3. Middle East & Africa by Country Sales Analysis
    • 7.7.4. Saudi Arabia Sales Analysis
    • 7.7.5. UAE Sales Analysis
    • 7.7.6. Israel Sales Analysis
    • 7.7.7. South Africa Sales Analysis
    • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE CONGESTIVE HEART FAILURE DRUGS COMPANIES

  • 8.1. Congestive Heart Failure Drugs Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9 . COMPANY PROFILES OF CONGESTIVE HEART FAILURE DRUGS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Bayer AG
    • 9.3.1. Company Overview
    • 9.3.2. Company Revenue
    • 9.3.3. Products
    • 9.3.4. Recent Developments
  • 9.4. Novartis AG
    • 9.4.1. Company Overview
    • 9.4.2. Company Revenue
    • 9.4.3. Products
    • 9.4.4. Recent Developments
  • 9.5. Merck & Co. Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Company Revenue
    • 9.5.3. Products
    • 9.5.4. Recent Developments
  • 9.6. AstraZeneca
    • 9.6.1. Company Overview
    • 9.6.2. Company Revenue
    • 9.6.3. Products
    • 9.6.4. Recent Developments
  • 9.7. Bristol-Myers Squibb Company
    • 9.7.1. Company Overview
    • 9.7.2. Company Revenue
    • 9.7.3. Products
    • 9.7.4. Recent Developments
  • 9.8. Amgen Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Company Revenue
    • 9.8.3. Products
    • 9.8.4. Recent Developments
  • 9.9. Boehringer Ingelheim International GmbH
    • 9.9.1. Company Overview
    • 9.9.2. Company Revenue
    • 9.9.3. Products
    • 9.9.4. Recent Developments
  • 9.10. Pfizer Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Company Revenue
    • 9.10.3. Products
    • 9.10.4. Recent Developments
  • 9.11. Johnson & Johnson Services Inc.
    • 9.11.1. Company Overview
    • 9.11.2. Company Revenue
    • 9.11.3. Products
    • 9.11.4. Recent Developments
  • 9.12. Otsuka Pharmaceutical Co. Ltd.
    • 9.12.1. Company Overview
    • 9.12.2. Company Revenue
    • 9.12.3. Products
    • 9.12.4. Recent Developments
  • 9.13. Eli Lilly and Company
    • 9.13.1. Company Overview
    • 9.13.2. Company Revenue
    • 9.13.3. Products
    • 9.13.4. Recent Developments
  • 9.14. Novo Nordisk A/S.
    • 9.14.1. Company Overview
    • 9.14.2. Company Revenue
    • 9.14.3. Products
    • 9.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies